Completed PHASE2 INTERVENTIONAL 1-arm NCT01176552

Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer

Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma

Sponsor: Kidney Cancer Research Bureau

Conditions Renal Cell Carcinoma

Interventions GM-CSF, IFN alpha and IL-2

Updated 6 times since 2017 Last updated: Aug 22, 2010 Started: May 31, 2004 Primary completion: Sep 30, 2008 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Cell Carcinoma and is currently completed. Kidney Cancer Research Bureau leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kidney Cancer Research Bureau

Data source: Kidney Cancer Research Bureau

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia